Asset Details
Do you wish to reserve the book?
In Vitro Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
In Vitro Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China
Do you wish to request the book?
In Vitro Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
In Vitro Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China
2022
Overview
To evaluate in vitro antibacterial activity of MRX-8 against gram-negative bacteria recently isolated from China, 765 clinical isolates were collected randomly from 2017 to 2020, including Enterobacterales and P. aeruginosa and A. baumannii , S. maltophilia, B. cepacia, Alcaligenes app. and Haemophilus spp. isolates. All strains were performed with antimicrobial susceptibility testing by broth microdilution method according to the CLSI 2021. Antimicrobial agents included MRX-8, polymyxin B, colistin, amikacin, ceftriaxone, ceftazidime, cefepime, ceftazidime-avibactam, cefoperazone-sulbactam, meropenem, ciprofloxacin, ampicillin, ampicillin-sulbactam and levofloxacin. For carbapenem-susceptible and carbapenem-resistant E.coli isolates, the MIC 50/90 of MRX-8 was 0.125/0.25 mg/L and 0.06/0.125 mg/L, respectively. For carbapenem-susceptible and carbapenem-resistant K. pneumoniae isolates, the MIC 50/90 of MRX-8 was 0.25/0.5 mg/L and 0.125/0.5 mg/L, respectively. For polymyxins (polymyxin B and colistin)-resistant E. coli and K. pneumoniae , MIC 50 of MRX-8 was 4-16 mg/L and MIC 90 was >32 mg/L. The MIC 50 and MIC 90 of MRX-8 for other Klebsiella spp. except K. pneumoniae , Citrobacter spp., S. enterica and Shigella spp. isolates ranged 0.06-0.125 mg/L and 0.06-0.25mg/L, respectively. For Morganella spp. , Proteus spp. , Providencia spp. , Serratia spp., S. maltophilia and B. cepacia , all MIC 50 of MRX-8 was >32mg/L. For carbapenem susceptible and resistant P. aeruginosa , the MIC 50 and MIC 90 of MRX-8 was both 1mg/L, and that for A. baumannii was 0.5mg/L and 0.5-1mg/L. For Alcaligenes spp. and Haemophilus spp., MIC 50/90 was 1/4 mg/L and 0.25/0.5 mg/L. MRX-8 was more effective against most clinically isolated gram-negative isolates, including carbapenem-resistant E. coli , K. pneumoniae , P. aeruginosa and A. baumannii , highlighting its potential as valuable therapeutics.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.